Formulation Development
Atavistik Bio Announces Research Collaboration With Pfizer
Atavistik Bio recently announced it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant…
ACELYRIN to Share New Phase 2 Data & Phase 3 Program Design for Subcutaneous Lonigutamab
ACELYRIN, INC. recently announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2…
Immuno-Oncology/Cancer Therapeutics Present Strongest Innovation Pipeline in Next 5 Years
Immuno-oncology (IO) drugs/cancer therapeutics represent one of the most promising areas of medical innovation in the next five years, fundamentally transforming how cancer is treated,…
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
TNF Pharmaceuticals, Inc. recently announced it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha (TNF-α) inhibitor drug…
Recognition of the American Society of Clinical Oncology of the Liver Protective Effect of Can-Fite’s Anti-Cancer Drug Namodenoson
Can-Fite BioPharma Ltd. recently announced that its work titled The Liver Protective Effect of the Anti-Cancer Drug Candidate Namodenoson is Mediated via Adiponectin will be presented…
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Wave Life Sciences Ltd. recently announced the submission of its first clinical trial application (CTA) for WVE-007 in obesity. WVE-007 is an investigational GalNAc-conjugated small…
Ikena Oncology & Inmagene Biopharmaceuticals Announce Agreement for Merger & Private Placement
Ikena Oncology, Inc. and Inmagene Biopharmaceuticals recently announced they have entered into a definitive merger agreement. In connection with the merger, Ikena has entered into…
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 & its Library of 500+ Proprietary Compounds
GRI Bio, Inc. recently announced the European Patent Office (EPO) has issued a decision to grant notice for patent application number 19,166,502 titled, Oxygenated Amino-…
Apollomics Announces Top-line Results for Phase 3 Trial of Uproleselan in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Inc. recently announced the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia.…
Shuttle Pharma Enters Sponsored Research Agreement With the University of California, San Francisco to Advance PSMA Development Program
Shuttle Pharmaceuticals Holdings, Inc. recently announced a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of Shuttle Diagnostics,…
Assembly Biosciences Announces $30.1 Million Investment & Accelerated Funding From Gilead
Assembly Biosciences, Inc. recently announced an equity investment of $20.1 million by Gilead Sciences, Inc. to purchase additional Assembly Bio common stock and an amendment…
IMUNON Announces Positive CMC Meeting With FDA for Advanced Ovarian Cancer Treatment
IMUNON, Inc. recently announced the positive outcome of a Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the US FDA regarding production of IMNN-001…
Gelteq Appoints New Chief Scientific Officer to Propel Innovative Ingestible Gel Technology
Gelteq Limited recently announced the appointment of Dr. Paul Wynne as its Chief Scientific Officer (CSO). Gelteq co-founder and CEO Nathan Givoni said “We believe…
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative
ABVC BioPharma, Inc. recently announced in response to the discontinuation of Prozac due to increasing concerns around side effects, ABVC believes its ABV-1504, which has…
Vandria Announces First Subjects Dosed in First-in-Human Phase 1 Trial of VNA-318 Brain-Penetrant Mitophagy Inducer
Vandria SA recently announced the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout…
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma
Coherus BioSciences, Inc. recently announced an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and…
Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
Polyrizon Ltd. announced it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading European-based Good Manufacturing Practice (GMP) manufacturer. This collaboration will…
Silo Pharma Initiates Pharmacokinetic & Tolerability Study for SP-26 Targeting Chronic Pain & Fibromyalgia
Silo Pharma, Inc. recently announced the initiation of a pharmacokinetic (PK) and tolerability study in partnership with its contract research organization (CRO), AmplifyBio. The study…
SCYNEXIS Initiates Dosing in Phase 1 Trial of a Second-Generation Fungerp Candidate for Invasive Fungal Infections
SCYNEXIS, Inc. recently announced it has completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247, the company’s second-generation…
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
Channel Therapeutics Corporation recently announced it achieved its endpoints in two pre-clinical in vivo models of its nerve block formulations for acute pain, showing material…
